Renovaro (RENB) Competitors $0.24 +0.01 (+4.46%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$0.24 +0.00 (+0.84%) As of 08/22/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RENB vs. BIOA, FTLF, CYBN, BTMD, NVCT, LXEO, GLSI, CRDF, ELDN, and BHSTShould you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include BioAge Labs (BIOA), FitLife Brands (FTLF), Cybin (CYBN), biote (BTMD), Nuvectis Pharma (NVCT), Lexeo Therapeutics (LXEO), Greenwich LifeSciences (GLSI), Cardiff Oncology (CRDF), Eledon Pharmaceuticals (ELDN), and BioHarvest Sciences (BHST). These companies are all part of the "pharmaceutical products" industry. Renovaro vs. Its Competitors BioAge Labs FitLife Brands Cybin biote Nuvectis Pharma Lexeo Therapeutics Greenwich LifeSciences Cardiff Oncology Eledon Pharmaceuticals BioHarvest Sciences Renovaro (NASDAQ:RENB) and BioAge Labs (NASDAQ:BIOA) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment. Does the media prefer RENB or BIOA? In the previous week, BioAge Labs had 2 more articles in the media than Renovaro. MarketBeat recorded 2 mentions for BioAge Labs and 0 mentions for Renovaro. BioAge Labs' average media sentiment score of 0.25 beat Renovaro's score of 0.00 indicating that BioAge Labs is being referred to more favorably in the news media. Company Overall Sentiment Renovaro Neutral BioAge Labs Neutral Which has preferable valuation & earnings, RENB or BIOA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRenovaroN/AN/A-$88.43M-$0.77-0.31BioAge LabsN/AN/A-$71.11MN/AN/A Do institutionals and insiders believe in RENB or BIOA? 71.4% of Renovaro shares are held by institutional investors. 0.5% of Renovaro shares are held by company insiders. Comparatively, 20.8% of BioAge Labs shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is RENB or BIOA more profitable? BioAge Labs' return on equity of -25.39% beat Renovaro's return on equity.Company Net Margins Return on Equity Return on Assets RenovaroN/A -60.38% -47.04% BioAge Labs N/A -25.39%-23.22% SummaryBioAge Labs beats Renovaro on 6 of the 7 factors compared between the two stocks. Get Renovaro News Delivered to You Automatically Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RENB vs. The Competition Export to ExcelMetricRenovaroMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.38M$3.11B$5.76B$9.61BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-0.3120.8831.1026.04Price / SalesN/A352.15435.05103.72Price / CashN/A43.1937.7358.48Price / Book0.278.129.536.61Net Income-$88.43M-$54.72M$3.26B$265.56M7 Day Performance-0.04%2.63%2.10%1.95%1 Month Performance-29.73%2.78%2.82%-0.37%1 Year Performance-65.09%11.01%30.56%19.02% Renovaro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RENBRenovaroN/A$0.24+4.5%N/A-63.7%$39.38MN/A-0.3120BIOABioAge LabsN/A$4.47-1.1%N/AN/A$160.25M$3.86M0.00N/AFTLFFitLife Brands4.1513 of 5 stars$17.03+1.6%$22.00+29.2%+8.0%$159.87M$64.47M20.2720CYBNCybin2.4428 of 5 stars$6.70-3.2%$85.00+1,168.8%N/A$157.94MN/A-1.5350News CoverageAnalyst RevisionBTMDbiote2.2307 of 5 stars$3.15+4.1%$6.00+90.8%-44.0%$157.47M$197.19M3.54194NVCTNuvectis Pharma3.8155 of 5 stars$6.18-4.2%$15.33+148.1%-4.6%$157.34MN/A-5.288Positive NewsLXEOLexeo Therapeutics2.3576 of 5 stars$4.78-2.8%$15.33+220.8%-59.8%$157.20M$650K-1.4558Analyst RevisionGLSIGreenwich LifeSciences1.7096 of 5 stars$11.61-3.3%$39.00+235.9%-13.9%$155.23MN/A-8.543Trending NewsAnalyst ForecastAnalyst RevisionCRDFCardiff Oncology1.599 of 5 stars$2.30-5.6%$10.10+340.1%+1.3%$153.35M$680K-2.6520ELDNEledon Pharmaceuticals1.4963 of 5 stars$2.55-2.1%$10.00+292.9%-11.9%$152.40MN/A-2.1810Short Interest ↑BHSTBioHarvest SciencesN/A$9.23-3.9%$13.67+48.1%N/A$151.56M$25.19M-13.19N/A Related Companies and Tools Related Companies BioAge Labs Alternatives FitLife Brands Alternatives Cybin Alternatives biote Alternatives Nuvectis Pharma Alternatives Lexeo Therapeutics Alternatives Greenwich LifeSciences Alternatives Cardiff Oncology Alternatives Eledon Pharmaceuticals Alternatives BioHarvest Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RENB) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renovaro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Renovaro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access